GlassScriptPhysician profile
Robin L Gallo
NPI 1497869440
$1,704.53
in general payments reported to CMS, 2019-2025
23 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $91.83 · 2023: $384 · 2024: $535 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $469.45 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $301.53 | 2023-2025 | Airsupra, Breztri |
| Phathom Pharmaceuticals, INC. | $124.73 | 2024-2025 | Voquezna |
| Pfizer INC. | $110.43 | 2023-2025 | |
| Janssen Biotech, INC. | $84.43 | 2025 | Tremfya |
| Novo Nordisk INC | $74.16 | 2022-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $60.56 | 2023-2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $57.00 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $51.70 | 2023-2025 | Entyvio |
| Ardelyx, INC. | $50.11 | 2023-2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $40.39 | 2021-2024 | Vaxneuvance, Capvaxive |
| Sumitomo Pharma America, INC. | $32.75 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $29.54 | 2023-2024 | |
| Mauna Kea Technologies, INC. | $27.25 | 2024 | |
| Braintree Laboratories, INC. | $26.01 | 2023 | Suflave |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $25.44 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $24.05 | 2024 | Crysvita |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.91 | 2021 | |
| Astellas Pharma US INC | $22.03 | 2023 | Veozah |
| Exact Sciences Corporation | $19.46 | 2024 | Cologuard Collection Kit |
| Braeburn INC. | $17.76 | 2025 | Brixadi |
| Aimmune Therapeutics, INC. | $16.56 | 2025 | Zenpep |
| Paratek Pharmaceuticals, INC. | $16.28 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Gallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.